Browsing by Author Chuang, W

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2016APASL consensus statements and recommendation on treatment of hepatitis CMcCaughan, Geoffrey William; Chuang, W; et al, Various; Ibrahim, Alaaeldin; Kanda, Tatsuo; Kumar, Manoj; Lesmana, Cosmas; Omata, Masao; Sollano, Jose; Wei, Lai; Yu, Ming-Lung; Central Clinical School: Centenary InstituteAPASL consensus statements and recommendation on treatment of hepatitis C, Hepatology International, vol.10, 5, 2016,pp 702-726
2016APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testingMcCaughan, Geoffrey William; Chuang, W; et al, Various; Ibrahim, Alaaeldin; Kanda, Tatsuo; Kumar, Manoj; Lesmana, Cosmas; Omata, Masao; Sollano, Jose; Wei, Lai; Yu, Ming-Lung; Central Clinical School: Centenary InstituteAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing, Hepatology International, vol.10, 5, 2016,pp 681-701
2016Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis BStrasser, Simone; Ahn, Sang Hoon; Caruntu, Florin A; Chuang, W; Elkashab, Magdy; et al, Various; Lim, Seng-Gee; Ma, Xiaoli; Marcellin, Patrick; Mehta, Rajiv; Tabak, Fehmi; Tak, Won Young; Central Clinical School: MedicineCombination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B, Gastroenterology, vol.150, 1, 2016,pp 134-144.e10
2013Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinGeorge, Jacob; Andreone, P; Chuang, W; et al, Various; Foster, G; Lee, C; Pianko, S; Piratvisuth, T; Sarin, S; Shah, S; Sood, A; Zeuzem, S; Western Clinical School: Westmead Millennium InstituteDecline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin, Journal of Viral Hepatitis, vol.20, 4, 2013,pp e115-e123
2012Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3George, Jacob; Andreone, P; Chuang, W; et al, various; Flisiak, Robert; Foster, G; Lee, C; Pianko, S; Piratvisuth, T; Sarin, S; Shah, S; Zeuzem, S; Western Clinical School: Westmead Millennium InstituteRandomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3, Journal of Viral Hepatitis, vol.19, 9, 2012,pp 623-634
2016A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Strasser, Simone; Chayama, Kazuaki; Chuang, W; et al, Various; Fainboim, Hugo; Farkkila, Martti; Foster, G; Gadano, Adrian; Gaeta, Giovanni B; Hezode, Christophe; Inada, Yukiko; Central Clinical School: MedicineA randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3, SpringerPlus, vol.5, 1, 2016,pp 1-12